美国青少年重症肌无力的治疗模式与疾病负担:基于医疗索赔数据库的队列研究
本研究利用美国Merative MarketScan数据库,纳入2008至2021年新诊断的630例青少年重症肌无力(JMG)患者,描述治疗模式与医疗资源利用。结果显示患者治疗升级迅速,青春期后发病者升级更快,但部分患者仍有高医疗资源利用,提示需要能快速控制疾病的新疗法。
要点
- JMG患者治疗升级迅速,青春期后发病者较青春期前更快升级至后线治疗。
- 随访第一年MG加重最常见,青春期后和青春期前分别为34.1%和30.3%。
- 胸腺切除率在维持性Ig/PLEX治疗期间最高。
核心结论
- JMG患者治疗升级迅速,青春期后发病者升级更快,但部分患者仍有高医疗资源利用,需要能快速控制疾病的新疗法。
研究设计与样本
- 基于美国Merative MarketScan研究数据库的队列研究,纳入2008至2021年新诊断的630例JMG患者,中位随访2.4年(范围0-13年)。
主要发现
- 随访第一年MG加重发生率在青春期后发病组为34.1%,青春期前发病组为30.3%。
- 胸腺切除率在维持性Ig/PLEX治疗期间最高,青春期后发病组为每100患者年34.62(95%CI 14.41-83.17),青春期前发病组为24.24(95%CI 9.10-64.60)。
- 青春期后发病组在维持性Ig/PLEX和非类固醇免疫抑制剂治疗(多为联合治疗)期间加重率最高,分别为每100患者年105.81(95%CI 68.99-162.29)和91.22(95%CI 65.80-126.47)。
- 青春期前发病组在非类固醇免疫抑制剂联合治疗和生物制剂治疗期间加重率最高,分别为每100患者年140.44(95%CI 115.45-170.85)和142.95(95%CI 46.10-443.23)。
- 随访第一年JMG相关住院率在青春期后发病组为36.0%,青春期前发病组为30.0%。
临床怎么用
- 临床应关注JMG患者治疗升级的快速性,尤其是青春期后发病者,并警惕随访第一年的疾病加重和高住院风险。
局限性
- 未评估治疗升级的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Juvenile myasthenia gravis (JMG) is a rare disorder defined as MG in patients younger than 18 years. Generalized JMG is more common in postpubertal than prepubertal patients. There are no formal international JMG treatment guidelines, and knowledge on treatment patterns and disease burden is limited. The aim of this study was to describe treatment patterns and health care resource utilization (HCRU) for patients with JMG and explore differences in disease presentation between prepubertal-onset (younger than 12 years) and postpubertal-onset (12-17 years) patients. METHODS: Patients with JMG, newly diagnosed from 2008 to 2021, were identified from the US Merative MarketScan® Research Databases. Patients were followed from the first JMG claim (diagnosis/treatment with acetylcholinesterase inhibitors, immunoglobulin [Ig], or plasma exchange [PLEX]). The primary outcome was JMG-related treatment changes during follow-up, assessed descriptively. Rates of MG exacerbation, thymectomy, and acute intravenous immunoglobulin/PLEX treatment were assessed. HCRU was evaluated. RESULTS: A total of 630 patients (64.1% female; mean [SD] age 9.07 [5.73] years; 57.6% prepubertal onset) were followed for a median (range) of 2.4 (0-13) years. Corticosteroids were started at a median (range) of 1.28 (0-37.02) and 3.19 (0-87.68) months from diagnosis for postpubertal-onset and prepubertal-onset patients, respectively. The rate of thymectomy was highest during treatment with maintenance Ig/PLEX (incidence rate [IR]; [95% CI] per 100 patient-years: 34.62 [14.41-83.17] for postpubertal-onset and 24.24 [9.10-64.60] for prepubertal-onset patients). MG exacerbations were most frequent during the first year of follow-up in both subgroups (34.1% and 30.3%). In postpubertal-onset patients, exacerbation was highest during treatment with maintenance Ig/PLEX and nonsteroid immunosuppressant therapy ([NSIST], mostly polytherapy) (IR [95% CI] 105.81 [68.99-162.29] and 91.22 [65.80-126.47]). For prepubertal-onset patients, exacerbation was most frequent during NSIST (polytherapy) and biologic treatment (IR [95% CI] 140.44 [115.45-170.85] and 142.95 [46.10-443.23]). JMG-related hospitalizations occurred in 36.0% and 30.0% of postpubertal-onset and prepubertal-onset patients, in the first year of follow-up. DISCUSSION: Patients with JMG escalated rapidly through the treatment hierarchy. Postpubertal-onset patients escalated more quickly to later-line treatments than prepubertal-onset patients. However, some patients continued to experience high HCRU, highlighting the need for new JMG treatments to provide rapid disease control. A limitation is that treatment escalation reasons were not evaluated.
引用
- Zhou J, Nilius S, Pilipczuk O, et al. Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases. Neurology. 2025. PMID: 40489715. doi:10.1212/WNL.0000000000213736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。